We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Summit Therapeutics (SMMT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Summit Therapeutics is one of 898 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. SMMT is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SMMT's full-year earnings has moved 3.76% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, SMMT has returned 28.75% so far this year. Meanwhile, the Medical sector has returned an average of -25.73% on a year-to-date basis. This means that Summit Therapeutics is outperforming the sector as a whole this year.
Looking more specifically, SMMT belongs to the Medical - Drugs industry, a group that includes 172 individual stocks and currently sits at #41 in the Zacks Industry Rank. On average, this group has lost an average of 31.28% so far this year, meaning that SMMT is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to SMMT as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Summit Therapeutics (SMMT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Summit Therapeutics is one of 898 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. SMMT is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SMMT's full-year earnings has moved 3.76% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, SMMT has returned 28.75% so far this year. Meanwhile, the Medical sector has returned an average of -25.73% on a year-to-date basis. This means that Summit Therapeutics is outperforming the sector as a whole this year.
Looking more specifically, SMMT belongs to the Medical - Drugs industry, a group that includes 172 individual stocks and currently sits at #41 in the Zacks Industry Rank. On average, this group has lost an average of 31.28% so far this year, meaning that SMMT is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to SMMT as it looks to continue its solid performance.